智雲健康(09955.HK)夥揚子江藥業戰略合作 拓慢性病領域數字化營銷服務
智雲健康(09955.HK)公布,與揚子江藥業訂立不具法律約束力的戰略合作協議,主要涉及某些慢性病領域的數字化營銷服務,共同探索及加深雙方在慢病管理領域的業務版圖和業務深度。
據此,雙方希望通過業務合作在內地的藥品數字化營銷領域建立長期戰略合作,以數字化SaaS的方式打造產業新業態,推動產業智能化、高端化和綠色化,提高慢病患者的藥品可及性。
揚子江藥業為跨地區營運的大型醫藥集團,具有產學研相結合、科工貿一體化能力,也是中國科技部命名的全國首批創新型企業。主要產品中西藥並舉,覆蓋15個治療領域和565個品規,其中102個品種出口38個國家或地區。揚子江香港為揚子江藥業的一名緊密聯繫人,是公司全球發售時的基石投資者,截至目前,其持有的公司股份少於公司已發行股份總數的0.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.